Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)

This study has been completed.

Sponsor:

Information provided by:

Dresden University of Technology

ClinicalTrials.gov Identifier:

NCT00153998

First received: September 8, 2005

Last updated: February 26, 2009

Last verified: April 2007

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	March 2008 (Final data collection date for primary outcome measure)

No publications provided by Dresden University of Technology

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010 Jan;11(1):38-47. Epub 2009 Nov 26.

To Top